Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunogen Inc (NQ: IMGN )

29.35 +13.29 (+82.75%)
Official Closing Price Updated: 4:15 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Immunogen Inc

< Previous 1 2 3 4 5 6 7 Next >
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
Why Abbvie Stock Popped Today
The company announces a major deal worth over $10 billion. 
Via The Motley Fool
Nasdaq Falls Over 100 Points; Cracker Barrel Shares Slide After Q1 Results
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday. The Dow traded up 0.88% to 35,742.35 while the NASDAQ fell 0.79% to 14,145.17. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Titan Machinery Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results. 
Via Benzinga
Health Care Company AbbVie Announces Acquisition of Immunogen
Via Benzinga
Where Immunogen Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Falls Sharply; Kroger Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded up 0.85% to 35,729.88 while the NASDAQ fell 0.71% to 14,156.60. The S&P... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal
AbbVie Inc (NYSE: ABBV) has agreed to acquire ImmunoGen Inc (NASDAQ: IMGN) and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC)... 
Via Benzinga
Why Is Soligenix (SNGX) Stock Up 285% Today?
Soligenix stock is rising higher on Thursday with heavy trading of SNGX shares after getting FDA approval for a Phase 2 clinical trial. 
Via InvestorPlace
Exposures Product Safety
Minim (MINM) Stock Soars 77% After Receiving Nasdaq Deficiency Notice
Minim stock is taking off with heavy trading of MINM shares on Thursday despite the company getting a delisting warning. 
Via InvestorPlace
What 4 Analyst Ratings Have To Say About Immunogen
Via Benzinga
Why Is ImmunoGen (IMGN) Stock Up 81% Today?
ImmunoGen stock is taking off on news that AbbVie is acquiring all outstanding shares of IMGN in a $10.1 billion acquisition deal. 
Via InvestorPlace
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal
IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of cancer drug Elahere. 
Via Investor's Business Daily
La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Jumps Around 200 Points; US Core PCE Inflation Slows In October
U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.56% to 35,630.09 while the... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
These Three Biotech Stocks Are Trading At A Discount
Investors exposed to the biotech sector have seen mixed results this year. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Sutro Biopharma's Lead Ovarian Cancer Candidate Is A Game Changer, Analyst Sees Huge Upside
Oppenheimer initiated coverage on Sutro Biopharma Inc (NASDAQ: STRO), representing around 200% potential upside.  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
These 8 Stocks Are Outperforming Nvidia In 2023
Carvana has surged 1,001%, leading huge winners this year. 
Via Investor's Business Daily
Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan
JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.